OBJECTIVES: Deep brain stimulation (DBS) has been established as a safe, effective therapy for movement disorders (Parkinson's disease, essential tremor, etc.), and its application is expanding to the treatment of other intractable neuropsychiatric disorders including depression and obsessive-compulsive disorder (OCD). Several published studies have supported the efficacy of DBS for severely debilitating OCD. However, questions remain regarding the optimal anatomic target and the lack of a bedside programming paradigm for OCD DBS. Management of OCD DBS can be highly variable and is typically guided by each center's individual expertise. In this paper, we review the various approaches to targeting and programming for OCD DBS. We also review the clinical experience for each proposed target and discuss the relevant neuroanatomy. MATERIALS AND METHODS: A PubMed review was performed searching for literature on OCD DBS and included all articles published before March 2012. We included all available studies with a clear description of the anatomic targets, programming details, and the outcomes. RESULTS: Six different DBS approaches were identified. High-frequency stimulation with high voltage was applied in most cases, and predictive factors for favorable outcomes were discussed in the literature. CONCLUSION: DBS remains an experimental treatment for medication refractory OCD. Target selection and programming paradigms are not yet standardized, though an improved understanding of the relationship between the DBS lead and the surrounding neuroanatomic structures will aid in the selection of targets and the approach to programming. We propose to form a registry to track OCD DBS cases for future clinical study design.
OBJECTIVES: Deep brain stimulation (DBS) has been established as a safe, effective therapy for movement disorders (Parkinson's disease, essential tremor, etc.), and its application is expanding to the treatment of other intractable neuropsychiatric disorders including depression and obsessive-compulsive disorder (OCD). Several published studies have supported the efficacy of DBS for severely debilitating OCD. However, questions remain regarding the optimal anatomic target and the lack of a bedside programming paradigm for OCD DBS. Management of OCD DBS can be highly variable and is typically guided by each center's individual expertise. In this paper, we review the various approaches to targeting and programming for OCD DBS. We also review the clinical experience for each proposed target and discuss the relevant neuroanatomy. MATERIALS AND METHODS: A PubMed review was performed searching for literature on OCD DBS and included all articles published before March 2012. We included all available studies with a clear description of the anatomic targets, programming details, and the outcomes. RESULTS: Six different DBS approaches were identified. High-frequency stimulation with high voltage was applied in most cases, and predictive factors for favorable outcomes were discussed in the literature. CONCLUSION: DBS remains an experimental treatment for medication refractory OCD. Target selection and programming paradigms are not yet standardized, though an improved understanding of the relationship between the DBS lead and the surrounding neuroanatomic structures will aid in the selection of targets and the approach to programming. We propose to form a registry to track OCD DBS cases for future clinical study design.
Authors: J V Lucey; D C Costa; G Adshead; M Deahl; G Busatto; S Gacinovic; M Travis; L Pilowsky; P J Ell; I M Marks; R W Kerwin Journal: Br J Psychiatry Date: 1997-10 Impact factor: 9.319
Authors: Benjamin D Greenberg; Donald A Malone; Gerhard M Friehs; Ali R Rezai; Cynthia S Kubu; Paul F Malloy; Stephen P Salloway; Michael S Okun; Wayne K Goodman; Steven A Rasmussen Journal: Neuropsychopharmacology Date: 2006-07-19 Impact factor: 7.853
Authors: A L Benabid; P Pollak; C Gervason; D Hoffmann; D M Gao; M Hommel; J E Perret; J de Rougemont Journal: Lancet Date: 1991-02-16 Impact factor: 79.321
Authors: Kenneth A Follett; Frances M Weaver; Matthew Stern; Kwan Hur; Crystal L Harris; Ping Luo; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda Journal: N Engl J Med Date: 2010-06-03 Impact factor: 91.245
Authors: B D Greenberg; L A Gabriels; D A Malone; A R Rezai; G M Friehs; M S Okun; N A Shapira; K D Foote; P R Cosyns; C S Kubu; P F Malloy; S P Salloway; J E Giftakis; M T Rise; A G Machado; K B Baker; P H Stypulkowski; W K Goodman; S A Rasmussen; B J Nuttin Journal: Mol Psychiatry Date: 2008-05-20 Impact factor: 15.992
Authors: Takashi Morishita; Sarah M Fayad; Masa-aki Higuchi; Kelsey A Nestor; Kelly D Foote Journal: Neurotherapeutics Date: 2014-07 Impact factor: 7.620
Authors: Nolan R Williams; Joseph J Taylor; Suzanne Kerns; E Baron Short; Edward M Kantor; Mark S George Journal: J Clin Psychiatry Date: 2014-08 Impact factor: 4.384
Authors: Peter J Grahn; Grant W Mallory; Obaid U Khurram; B Michael Berry; Jan T Hachmann; Allan J Bieber; Kevin E Bennet; Hoon-Ki Min; Su-Youne Chang; Kendall H Lee; J L Lujan Journal: Front Neurosci Date: 2014-06-25 Impact factor: 4.677